SCHEDULE 13G/A: Invus Entities and Raymond Debbane Disclose Passive Stake in Vigil Neuroscience, Inc. Below 5%

Multiple Invus-affiliated entities and Raymond Debbane have filed an amended Schedule 13G, disclosing beneficial ownership of Vigil Neuroscience, Inc. Common Stock, with Raymond Debbane holding 4.9% as of December 31, 2024.

Summary

• Invus Public Equities, L.P. and its controlling entities (Invus Public Equities Advisors, LLC, Invus Global Management, LLC, and Siren, L.L.C.) each report beneficial ownership of 1,828,691 shares of Vigil Neuroscience, Inc. Common Stock, representing 4.5% of the class.
• Avicenna Life Sci Master Fund LP and its controlling entities (Avicenna Life Sci Master GP LLC and Ulys, L.L.C.) each report beneficial ownership of 162,347 shares, representing 0.4% of the class.
• Mr. Raymond Debbane, as the managing member of Siren, L.L.C. and Ulys, L.L.C., is deemed to beneficially own a total of 1,991,038 shares, which constitutes 4.9% of Vigil Neuroscience, Inc.'s Common Stock.
• The beneficial ownership percentages are calculated based on 40,879,485 shares of Common Stock outstanding as of October 31, 2024, as reported by Vigil Neuroscience, Inc. in its Form 10-Q filed on November 7, 2024.
• The filing is an Amendment No. 1 to a Schedule 13G, indicating a change or update to previously reported passive beneficial ownership.

Sentiment

Score: 5

Explanation: The document is a neutral, factual disclosure of beneficial ownership, as is typical for a Schedule 13G filing. It provides no positive or negative operational or financial news about the company itself.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding the issuer's future performance or the reporting persons' future investment intentions beyond the passive nature of their current holdings.

Industry Context

This filing is a routine disclosure of passive beneficial ownership in a publicly traded biotechnology company, Vigil Neuroscience, Inc. It reflects an investment firm's and related entities' stake, which is common practice in the investment industry for portfolio management and regulatory compliance. The disclosed ownership percentages are below the 5% threshold that typically triggers more active reporting (Schedule 13D) or significant market attention, suggesting a passive investment strategy.

Related Party Transactions

• The filing details a chain of control among the reporting persons: Invus Public Equities, L.P. is controlled by Invus Public Equities Advisors, LLC, which is controlled by Invus Global Management, LLC, which is controlled by Siren, L.L.C. Similarly, Avicenna Life Sci Master Fund LP is controlled by Avicenna Life Sci Master GP LLC, which is controlled by Ulys, L.L.C. Mr. Raymond Debbane is the managing member of both Siren, L.L.C. and Ulys, L.L.C., establishing a clear related party structure for the beneficial ownership.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant passive ownership stakes in Vigil Neuroscience, Inc., indicating that these entities and individuals hold a notable, albeit non-controlling, portion of the company's stock.

Key Dates

Keywords

Vigil Neuroscience, SEC filing, Schedule 13G, beneficial ownership, Invus Public Equities, Raymond Debbane, common stock, passive investment, equity stake